Sepsis - Pipeline Review, H2 2015 Now Available at iData Insights Sepsis - Pipeline Review, H2 2015 Summary Global Markets Direct s, Sepsis - Pipeline Review, H2 2015 , provides an overview of the Sepsis s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Sepsis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Sepsis and special features on late-stage and discontinued projects. Global Markets Direct s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-inclass products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Sepsis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Sepsis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Sepsis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Sepsis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Sepsis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Sepsis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=124189/sepsispipeline-review-h2-2015 To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landing-page.php?id=124189/sepsispipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Sepsis Overview 9 Therapeutics Development
1
10 Pipeline Products for Sepsis - Overview 10 Pipeline Products for Sepsis - Comparative Analysis 11 Sepsis - Therapeutics under Development by Companies 12 Sepsis - Therapeutics under Investigation by Universities/Institutes 17 Sepsis - Pipeline Products Glance 19 Late Stage Products 19 Clinical Stage Products 20 Early Stage Products 21 Unknown Stage Products 22 Sepsis - Products under Development by Companies 23 Sepsis - Products under Investigation by Universities/Institutes 27 Sepsis - Companies Involved in Therapeutics Development 29 Adrenomed AG 29 Altor BioScience Corporation 30 Am-Pharma B.V. 31 Arch Biopartners, Inc. 32 Asahi Kasei Pharma Corp. 33 Biomedica Management Corporation 34 Cell2B S.A. 35 Chiesi Farmaceutici SpA 36 Chiome Bioscience, Inc. 37 Cilian AG 38 Cognosci, Inc. 39 Diomune S.L 40 Endacea, Inc. 41 Evec, Inc. 42 Huons Co., Ltd. 43 Immune Response BioPharma, Inc. 44 Immunethep, SA 45 ImmunNovative Developments SL 46 InflaRx GmbH 47 Integrated BioTherapeutics, Inc. 48 ISU ABXIS Co.,Ltd.
2
49 Lead Discovery Center GmbH 50 Navigen Pharmaceuticals, Inc. 51 Novadiscovery SAS 52 Ocata Therapeutics, Inc. 53 OncoImmune, Inc. 54 Opsona Therapeutics Limited 55 ProThera Biologics, LLC. 56 Ribomic Inc. 57 Silence Therapeutics Plc 58 Stemedica Cell Technologies, Inc. 59 Syntiron LLC 60 Takeda Pharmaceutical Company Limited 61 TiGenix NV 62 VBS Pharmaceuticals 63 XImmune AB 64 Sepsis - Therapeutics Assessment 65 Assessment by Monotherapy Products 65 Assessment by Target 66 Assessment by Mechanism of Action 68 Assessment by Route of Administration 70 Assessment by Molecule Type 72 Drug Profiles 74 3K3A-APC - Drug Profile 74 7-H9 - Drug Profile 76 AB-022 - Drug Profile 78 AcPepA - Drug Profile 79 adrecizumab - Drug Profile 80 Alpha B Crystalline - Drug Profile 81 ALT-836 - Drug Profile 82 AM/AMBP-1 - Drug Profile 84 Aspidasept - Drug Profile 87 Atu-111 - Drug Profile 88 bacterial sepsis vaccine - Drug Profile
3
89 BaxB-01 - Drug Profile 90 BaxG-03 - Drug Profile 91 BaxM-159 - Drug Profile 92 BRL-44408 - Drug Profile 93 BTZO-2 - Drug Profile 95 CAR Peptide - Drug Profile 96 ceftaroline fosamil - Drug Profile 97 CN-16 - Drug Profile 99 COG-133 - Drug Profile 100 Cx-611 - Drug Profile 102 Drug for Sepsis - Drug Profile 104 Drugs for Sepsis - Drug Profile 105 Drugs to Inhibit Aldose Reductase for Immunology, Ophthalmology, Infectious Disease, Metabolic and Respiratory Disorders - Drug Profile 106 Drugs to Inhibit Sialidase for Sepsis - Drug Profile 107 Escherichia coli vaccine - Drug Profile 108 EV-007 156 - Drug Profile 109 Glyco-23 - Drug Profile 110 HBN-1 - Drug Profile 111 HBN-3 - Drug Profile 112 HBN-4 - Drug Profile 113 HU-003 - Drug Profile 114 IFX-1 - Drug Profile 115 ImmStem - Drug Profile 116 ImmuneSafe - Drug Profile 117 IND-005 - Drug Profile 119 IND-006 - Drug Profile 120 IR-999 - Drug Profile 121 ISU-201 - Drug Profile 122 Klebsiella pneumoniae vaccine - Drug Profile 123 L-97-1 - Drug Profile 124 LB-1148 - Drug Profile 126 LR-17 - Drug Profile
4
127 M-33 - Drug Profile 128 meropenem - Drug Profile 129 Mesenchymal Stem Cells - Drug Profile 130 Metablok - Drug Profile 132 Micselon - Drug Profile 133 Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders - Drug Profile 134 Monoclonal Antibody 1 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 135 Monoclonal Antibody 2 to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease - Drug Profile 136 Monoclonal Antibody for Pancreatic Cancer, Sepsis and Disseminated Intravascular Coagulation - Drug Profile 137 Monoclonal Antibody to Inhibit Aminoprocalcitonin for Sepsis, SIRS, Acute Lung Injury and Alzheimer's Disease Drug Profile 138 Nanotherapeutics - Drug Profile 140 NAV-838 - Drug Profile 141 OPN-305 - Drug Profile 143 Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - Drug Profile 145 Polysaccharide for Sepsis - Drug Profile 147 Proteins to Inhibit Furin for Anthrax Intoxication and Sepsis - Drug Profile 148 RBM-005 - Drug Profile 149 Recombinant Enzyme to Replace Alkaline Phosphatase for Sepsis - Drug Profile 150 Recombinant Human Alkaline Phosphatase - Drug Profile 151 Recombinant Protein for Acute Lung Injury, Sepsis and Chronic Inflammation - Drug Profile 152 Recombinant Protein for Sepsis - Drug Profile 153 Recombinant Protein for Sepsis, Inflammatory bowel disease, Acute Kidney Injury, Acute radiation syndrome and Ischemic organ injury - Drug Profile 154 Recombinant Protein to Target Lipopolysaccharide for Sepsis - Drug Profile 155 SAN-101 - Drug Profile 156 Slit2N - Drug Profile 157 Small Molecule for Immunology, CNS, Cardiovascular and Infectious Disease - Drug Profile 159 Small Molecule to Inhibit DDAH1 for Sepsis - Drug Profile 160 Small Molecules for Inflammatory Diseases and Sepsis - Drug Profile 161 Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 162 staphylococcus aureus (bivalent) vaccine - Drug Profile 163 Stem Cell Therapy for Autoimmune Diseases - Drug Profile 164 Synthetic Peptide to Inhibit TREM-1 for Cancer and Infectious Diseases - Drug Profile
5
165 Synthetic Peptides for Immunology and Infectious Diseases - Drug Profile 166 Synthetic Peptides for Infectious Disease - Drug Profile 167 Synthetic Peptides for Inflammation and Infectious Disorders - Drug Profile 168 Synthetic Peptides for Sepsis, Bacterial and Fungal Infections - Drug Profile 169 Synthetic Peptides to Inhibit LPS for Bacterial and Viral Infections - Drug Profile 170 TF-0003 - Drug Profile 171 thrombomodulin alfa - Drug Profile 172 TRX-306 - Drug Profile 174 vancomycin hydrochloride - Drug Profile 175 Yersinia pestis vaccine - Drug Profile 176 Sepsis - Recent Pipeline Updates 177 Sepsis - Dormant Projects 188 Sepsis - Discontinued Products 192 Sepsis - Product Development Milestones 193 Featured News & Press Releases 193 Appendix 198 Methodology 198 Coverage 198 Secondary Research 198 Primary Research 198 Expert Panel Validation 198 Contact Us 198 Disclaimer Read More http://www.idatainsights.com/reports-landing-page.php?id=124189/sepsis-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line.
Contact Us: iData Insights Tel: 1-866-237-2965
6
Web: http://www.idatainsights.com Email: info@idatainsights.com
About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects.
7